Literature DB >> 1060505

Initial features and prognosis in 363 children with acute lymphocytic leukemia.

J V Simone, M S Verzosa, J A Rudy.   

Abstract

The relationship of a variety of initial features and the outcome of therapy was analyzed for 363 children with acute lymphocytic leukemia (ALL). All had entered "total therapy" studies between 1962 and 1971. The standard for comparing outcome of therapy was whether patients with a given feature attained or exceeded the median duration of complete remission, hematologic remission or survival for the group. The results showed that, in general, the more massive or extensive the disease at diagnosis, the poorer the outcome. Factors associated with a significantly poorer prognosis included: initial leukocyte count above 100,000/mm; spleen enlargement greater than 5 cm; mediastinal involvement and early CNS involvement. Children over 10 years old at diagnosis and Negro children also had a poor prognosis. From another viewpoint features were examined for patients who attained at least 3 years of continuous complete remission. This confirmed some earlier findings and, in addition, showed that children under 2 years of age at diagnosis or with hepatomegaly over 5 cm were less likely to attain this goal. With the exception of early CNS involvement, however, patients with excellent responses to therapy were found with each factor of poor prognosis. Two major factors were not analyzed because their relationship to prognosis is generally accepted: therapeutic differences and acute nonlymphocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1060505     DOI: 10.1002/cncr.2820360926

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Prognostic factors in childhood acute lymphoblastic leukaemia.

Authors:  J Armstrong; M Pomeroy; J J Fennelly; S Cahalane
Journal:  Ir J Med Sci       Date:  1990-02       Impact factor: 1.568

2.  Aplastic anemia--and early phase preceding acute lymphatic leukemia.

Authors:  V P Choudhry; R K Adhikari; A K Saraya
Journal:  Indian J Pediatr       Date:  1982 May-Jun       Impact factor: 1.967

Review 3.  The T lymphoblastic malignancies.

Authors:  L M Nadler; E L Reinherz; S F Schlossman
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL.

Authors:  Alessandra Di Grande; Sofie Peirs; Paul D Donovan; Maaike Van Trimpont; Julie Morscio; Beatrice Lintermans; Lindy Reunes; Niels Vandamme; Steven Goossens; Hien Anh Nguyen; Arnon Lavie; Richard B Lock; Jochen H M Prehn; Pieter Van Vlierberghe; Triona Ní Chonghaile
Journal:  Blood Adv       Date:  2021-04-13

Review 5.  Childhood acute lymphocytic leukemia: progress and problems in treatment.

Authors:  W P Bowman
Journal:  Can Med Assoc J       Date:  1981-01-15       Impact factor: 8.262

6.  Acute lymphoblastic leukaemia under 2 years.

Authors:  A D Leiper; J Chessells
Journal:  Arch Dis Child       Date:  1986-10       Impact factor: 3.791

7.  [Long-term survival of adults with acute leukemia [author's transl)].

Authors:  H C Benöhr; G Reu; K Wilms; H D Waller
Journal:  Blut       Date:  1980-06

8.  Effects of cell density on drug-induced cell kill kinetics in vitro (inoculum effect).

Authors:  T Ohnuma; H Arkin; J F Holland
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

9.  Adult acute lymphoblastic leukaemia: a study of prognostic features and response to treatment over a ten year period.

Authors:  R E Marcus; D Catovsky; S A Johnson; W M Gregory; J G Talavera; J M Goldman; D A Galton
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

10.  Relationship between the pretreatment proliferative activity of marrow blast cells and prognosis of acute lymphoblastic leukaemia of childhood.

Authors:  J H Scarffe; I M Hann; D I Evans; P Morris Jones; M K Palmer; J S Lilleyman; D Crowther
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.